Literature DB >> 3141509

Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma.

F H Valone1, L B Epstein.   

Abstract

The capacity of IL-1-beta, TNF, and IFN-gamma to stimulate platelet-activating factor (PAF) synthesis by human monocytes is examined in our report. All three cytokines induced PAF synthesis in a novel biphasic pattern with peaks of PAF synthesis 1 to 2 and 6 to 8 h after stimulation of the monocytes. In contrast, calcium ionophore A23187 elicited a single peak of early PAF synthesis. PAF in the early peak was largely retained intracellularly whereas PAF in the late peak was largely released into culture fluids. Combinations of cytokines were subadditive or antagonistic in inducing PAF synthesis. Cycloheximide inhibited the late peak of PAF synthesis indicating that protein synthesis is required for synthesis of the phospholipid PAF. Specific antibodies to TNF or IL-1-beta inhibited the late peak of PAF synthesis induced by IFN-gamma indicating that late PAF synthesis is dependent on cytokine synthesis. The quantities of PAF produced by cytokine-activated monocytes are sufficient to activate human monocytes. Thus, these studies suggest that PAF may mediate in part monocyte activation by cytokines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141509

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage.

Authors:  Y Hirashima; S Nakamura; S Endo; N Kuwayama; Y Naruse; A Takaku
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

2.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins.

Authors:  P Braquet; D Hosford; P Koltz; J Guilbaud; M Paubert-Braquet
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

4.  Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor.

Authors:  N M Ruis; J K Rose; F H Valone
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor.

Authors:  I H Choi; T Y Ha; D G Lee; J S Park; J H Lee; Y M Park; H K Lee
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 6.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

7.  Increased expression and occupancy of receptors for tumour necrosis factor on blood monocytes from tuberculosis patients.

Authors:  J Cadranel; C Philippe; B Philippe; B Milleron; B Fouqueray; C Mayaud; L Baud
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Roles of tumor necrosis factor and macrophages in lipopolysaccharide-induced accumulation of neutrophils in cutaneous air pouches.

Authors:  A G Harmsen; E A Havell
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

Review 9.  Leukotriene B4 and platelet-activating factor in human skin.

Authors:  L Michel; L Dubertret
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 10.  HIV-related neuronal injury. Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists.

Authors:  S A Lipton
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.